LupuzorTM may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable.
Discovered by Sylviane Muller’s team in the CNRS Immunopathologie et Chimie Thérapeutique laboratory, in Strasbourg, this peptide is the subject of a CNRS patent (granted in 2009) and has already successfully completed phases I and II of its regulatory clinical trials, supervised by ImmuPharma-France. An international phase III pivotal trial1, also managed by this company, will begin in a few days’ time in the US when the first patient starts the treatment, before the trial is extended to Europe. Phase III is the last stage in the testing of a candidate drug, before it can be given market approval. The launch of phase III was the subject of a meeting involving around a hundred physicians on December 11-12, in Paris.
Lupus2 is a chronic autoimmune disease that affects more than five million people worldwide (around 30,000 in France), 90% of whom are women. It is characterized by the production of autoantibodies that attack different organs (skin, joints, vascular system, brain, kidneys) and cause inflammation, hence the broad range of possible symptoms: skin lesions, joint pain, thromboses, psychotic episodes, etc. To alleviate this disease with many causes, only palliative treatments are available at present, most of which are non-specific: corticosteroids and immunosuppressants, but they also weaken the immune system. Although they can stop autoimmune attacks, they also render patients highly susceptible to multiple infections. It was therefore urgent to develop a more targeted therapy.
The team led by Sylviane Muller, who received the 2015 CNRS Medal of Innovation3, developed a family of peptides (protein fragments) that can specifically correct dysfunction of the immune system4. One of these peptides, called P1405, proved capable of delaying the development of lupus in affected mice, while preserving their immune systems’ ability to fight infective agents. Since then, phase I and II clinical trials have been carried out6 by the company ImmuPharma-France, which holds an exclusive license for the patents that protect this family of peptides, all owned by the CNRS or filed as joint property. During phase II trials, the disease regressed in 62% of patients after 3 months of treatment: this is the best result ever to have been achieved for this pathology.
Following these successes, ImmuPharma-France launched its pivotal phase III trial. In the same way as during the phase IIb trials, the candidate drug will be administered under double-blind conditions once a month by the subcutaneous route, at a rate of 200 µg per injection, but the duration of treatment will be extended to a year, as opposed to 3 months previously. Two hundred patients will be included in this trial, spread across 45 centers (10 in the US and 35 in Europe7). The first patients will be recruited in the US by the end of 2015. In Europe, the trial should be starting in mid-January in the first centers, which include those in France. Recruitment should be completed by mid-2016 and the final results are anticipated at the end of 2017.
The first Investigators’ Meeting for the phase III trial took place on December 11 and 12 in Paris, and involved around a hundred American and European physicians.
Once this final phase of clinical trials is completed, and provided the results confirm those of phase IIb, LupuzorTM could be put on the market and subsequently play a central role in the treatment of patients with lupus.
According to preclinical findings, LupuzorTM may also be effective in other chronic autoimmune pathologies, such as Sjögren’s syndrome (dry eye syndrome) or Crohn’s disease (an autoimmune disease that causes chronic intestinal inflammation). Fundamental studies on these promising leads are now underway in Sylviane Muller’s laboratory.
The Latest on: Lupus
via Google News
The Latest on: Lupus
- Lupus Foundation of America Summer Fellowship Program Awards Grants to Six Young Scientistson August 2, 2022 at 5:00 am
The Lupus Foundation of America announces six recipients of the 2022 Gina M. Finzi Memorial Student Summer Fellowship Program, which provides grant and mentorship support to young scientists pursuing ...
- Exploring Options For Black Women With Lupuson August 1, 2022 at 12:13 pm
Lupus can cause a lot of different health problems, there are many kinds of medicines used to treat it. From Antimalarials that help reduce autoantibodies and immunosuppressives to support your immune ...
- Black Women & Lupuson August 1, 2022 at 8:14 am
According to an NIH study, African-Americans in the U.S. have three to four times greater prevalence of lupus, risk of developing lupus at an earlier age and lupus-related disease activity, damage and ...
- Investigational drug Litifilimab effective against cutaneous lupus erythematosus: LILAC trialon August 1, 2022 at 7:15 am
"Longer and larger trial are, however, needed to determine the safety and effects of litifilimab for cutaneous lupus erythematosus treatment, "Victoria P. Werth, and colleagues wrote in their study.
- New lupus treatments offer a better chance for remissionon August 1, 2022 at 6:50 am
One of the most difficult things about lupus, a chronic autoimmune disease, is that people who have it don't always realize it—they know something's not right, but they're not sure what. They may feel ...
- Why You Should Avoid Drinking Alcohol When Taking Lupus Medicationon July 30, 2022 at 9:00 pm
Knowing what to eat or drink can be difficult when you have lupus. Some foods and beverages may trigger flare-ups or interact with your meds.
- LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritison July 27, 2022 at 1:33 pm
When proteins produced by the immune cells called antibodies attack the kidney tissue, inflammation, or lupus nephritis results. Eight out of ten children with lupus will have kidney damage, which ...
- First Drug OK'd for Lupus Nephritis in Kidson July 27, 2022 at 11:46 am
Already approved in adults with lupus nephritis, belimumab's new indication is specifically for children 5 to 17 years of age on standard therapy. The BLyS-specific inhibitor is also approved in ...
- Belimumab becomes first FDA-approved drug for pediatric lupus nephritison July 27, 2022 at 10:35 am
The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.
- Woman survives life-threatening conditions before Lupus diagnosison July 27, 2022 at 9:37 am
Cheryl Yetz, from Missouri City, is on a mission to make sure others know the warning signs for an earlier diagnosis than she received.
via Bing News